Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Sio Gene Therapies Inc. SIOX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
26/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Sio Gene Therapies Inc. (SIOX) is a Biotechnology company in the Healthcare sector, currently trading at $0.48. It has a SharesGrow Score of 25/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Net income is $72M (loss), growing at -7.5%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $3M against $60M equity (Debt-to-Equity (D/E) ratio 0.04, conservative). Current ratio is 5.52 (strong liquidity). Debt-to-assets is 3.4%. Total assets: $75M.

Analyst outlook: 1 / 4 analysts rate SIOX as buy (25%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 20/100 (Fail), Income ?/100 (Fail).

SIOX SharesGrow Score Overview

33/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 20/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SIOX

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
SIOX: +0%/yr revenue is, -7.5%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet SIOX: Debt-to-Equity (D/E) ratio 0.04 (conservative), Current ratio is 5.52 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
SIOX: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
20/100
Analyst outlook: 1 / 4 analysts rate SIOX as buy (25%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.25-0.5
Volume7.59K
Avg Volume (30D)62.41K
Beta (1Y)1.09
Dividend Yield$0.4350
Share Statistics
EPS (TTM)-0.98
Shares Outstanding$73.21M
IPO Date2015-06-11
Employees12
CEODavid W. Nassif
Financial Highlights & Ratios
EBITDA$-70.94M
Net Income$-71.89M
Operating Income$-72.27M
Total Cash$63.73M
Total Debt$2.52M
Net Debt$-61.21M
Total Assets$75.08M
Price / Earnings (P/E)-0.5
Analyst Forecast
Rating ConsensusHold
Analysts Covering4
Buy 25% Hold 50% Sell 25%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS8293991043

Price Chart

Track all markets on TradingView
SIOX
Sio Gene Therapies Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.25 52WK RANGE 0.50

People Also View

NUVB
NUVB
Nuvation Bio Inc.
$4.85
+3.19%
 CTMX
CTMX
CytomX Therapeutics, Inc.
$4.54
+3.42%
 XOMA
XOMA
XOMA Corporation
$39.41
+1.97%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.44
+0.68%
 MNPR
MNPR
Monopar Therapeutics Inc.
$57.92
+3.28%
 RZLT
RZLT
Rezolute, Inc.
$3.56
-1.36%
 SRZN
SRZN
Surrozen, Inc.
$31.07
+4.05%
 TARA
TARA
Protara Therapeutics, Inc.
$5.13
+1.18%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message